Biosimilars event 2015

On the 8th May PrescQIPP hosted an all-day event centred on the biosimilar of infliximab. The aim was to bring clinicians, nurses and pharmacists together to discuss the key issues relating to the implementation and uptake of the biosimilar in clinical practice.

Initial presentations focussed on the science of biologics and biosimilars for those unfamiliar with the technical aspects underpinning these drugs and how they are regulated. Following on from this were two sessions that aimed to explain the commissioners viewpoint and the key issues from the patients’ perspective.

Some of the latest data relating to real-world usage in gastroenterology patients was discussed after lunch. Next PrescQIPP’s secondary care lead, James Kent, attempted to demystify some of the more contentious issues relating to biosimilars. Lastly there were two presentations from clinicians based in rheumatology and gastroenterology.

Both of these talks highlighted the key issues within these two specialities and possible approaches to encourage usage going forward. In particular the talk by Dr Fraser Cummings, from Southampton, illustrated what is possible when commissioners and providers work together to maximise outcomes for patients and the local health economy.